MedTrace Logo

Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLC

NCT02179567 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2015-09-28

No results posted yet for this study

Summary

The investigators propose to study the efficacy and safety of the combination of Docetaxel plus Bevacizumab in a Phase II trial of elderly subjects with non-small cell lung cancer

Conditions

Interventions

DRUG

Docetaxel

Docetaxel: 60mg/m2 i.v on day 1. Cycle repeated ever 3 weeks

DRUG

Bevacizumab

Bevacizumab: 7.5 mg/kg, iv on day 1. Cycle repeated every 3 weeks

Sponsors & Collaborators

  • Hellenic Oncology Research Group

    lead OTHER

Principal Investigators

  • Lambros Vamvakas, MD · University Hospital of Herklion

  • Athanasios Karambeazis, MD · Medical Oncology Unit NIMTS (Veterans Hospital)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02179567 on ClinicalTrials.gov